Abstract
The penetration characteristics of piperacillin-tazobactam into cortical and cancellous bone tissues were investigated in 10 patients undergoing total hip replacement. The concentration ratios of piperacillin/tazobactam were 9.4 +/- 1.8 in cancellous bone tissue and 8.0 +/- 2.2 in cortical bone tissue, which were close to the 8:1 ratio of drugs administered. The mean ratios of drug concentrations in bone and plasma for cancellous and cortical tissue were 23 and 18%, respectively, for piperacillin and 26 and 22%, respectively, for tazobactam. The concentrations of tazobactam achieved are sufficient to exert anti-beta-lactamase activity and supportive of clinical trials involving bone and joint infections, including those caused by beta-lactamase-producing pathogens.
Full text
PDF


Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adam D., Heilmann H. D., Weismeier K. Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin. Antimicrob Agents Chemother. 1987 Jun;31(6):935–939. doi: 10.1128/aac.31.6.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Aronoff S. C., Jacobs M. R., Johenning S., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother. 1984 Oct;26(4):580–582. doi: 10.1128/aac.26.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis Suppl. 1990;74:23–33. [PubMed] [Google Scholar]
- Fortner C. L., Finley R. S., Schimpff S. C. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy. 1982 Nov-Dec;2(6):287–299. doi: 10.1002/j.1875-9114.1982.tb03202.x. [DOI] [PubMed] [Google Scholar]
- Grimer R. J., Karpinski M. R., Andrews J. M., Wise R. Penetration of amoxycillin and clavulanic acid into bone. Chemotherapy. 1986;32(3):185–191. doi: 10.1159/000238414. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Pfaller M. A., Fuchs P. C., Aldridge K., Allen S. D., Gerlach E. H. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):489–494. [PubMed] [Google Scholar]
- Kinzig M., Sörgel F., Brismar B., Nord C. E. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992 Sep;36(9):1997–2004. doi: 10.1128/aac.36.9.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ryan D. M., Cars O. A problem in the interpretation of beta-lactam antibiotic levels in tissues. J Antimicrob Chemother. 1983 Sep;12(3):281–284. doi: 10.1093/jac/12.3.281. [DOI] [PubMed] [Google Scholar]
- Sörgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):39–60. doi: 10.1093/jac/31.suppl_a.39. [DOI] [PubMed] [Google Scholar]
- Weismeier K., Adam D., Heilmann H. D., Koeppe P. Penetration of amoxycillin/clavulanate into human bone. J Antimicrob Chemother. 1989 Nov;24 (Suppl B):93–100. doi: 10.1093/jac/24.suppl_b.93. [DOI] [PubMed] [Google Scholar]
- Winston D. J., Murphy W., Young L. S., Hewitt W. L. Piperacillin therapy for serious bacterial infections. Am J Med. 1980 Aug;69(2):255–261. doi: 10.1016/0002-9343(80)90386-1. [DOI] [PubMed] [Google Scholar]